Penn State University Background
In both diabetic retinopathy (DR) and age-related macular degeneration (AMD), patients’ vision is compromised by cell death, inflammation, growth of abnormal blood vessels, and edema. Most available drugs tackle blood vessel complications in late stage AMD but ignore the earlier occurring pathological events.
Researchers have designed proprietary PEDF-derived small peptides to address inflammation and angiogenesis that result in cell death and vascular leakage. This novel topical diabetic retinopathy treatment provides safer, more effective, and noninvasive PEDF peptide treatment at both the early and late stages of the disease ().
Researchers’ proprietary topical peptide technology has the following potential advantages over competing products:
Addresses problems of both early and late-stage DR and AMD;
Easy to manufacture;
Can be used as needed by patients and at different doses;
Can safely be applied at home;
Easy to differentiate its composition;
Costs ~50% less than competing drugs;
Synergistic with other ocular treatments;
Likely effective for other retinal diseases.
Seeking research collaboration and licensing opportunities.